MX2011009669A - Composición farmacéutica de liberación controlada con resistencia a la influencia de etanol mediante un revestimiento compuesto de una mezcla polimérica y excipientes. - Google Patents
Composición farmacéutica de liberación controlada con resistencia a la influencia de etanol mediante un revestimiento compuesto de una mezcla polimérica y excipientes.Info
- Publication number
- MX2011009669A MX2011009669A MX2011009669A MX2011009669A MX2011009669A MX 2011009669 A MX2011009669 A MX 2011009669A MX 2011009669 A MX2011009669 A MX 2011009669A MX 2011009669 A MX2011009669 A MX 2011009669A MX 2011009669 A MX2011009669 A MX 2011009669A
- Authority
- MX
- Mexico
- Prior art keywords
- influence
- excipients
- pharmaceutical composition
- controlled release
- coating
- Prior art date
Links
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 title abstract 6
- 238000013270 controlled release Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000000546 pharmaceutical excipient Substances 0.000 title abstract 2
- 239000011248 coating agent Substances 0.000 title 1
- 238000000576 coating method Methods 0.000 title 1
- 229920002959 polymer blend Polymers 0.000 title 1
- 239000004480 active ingredient Substances 0.000 abstract 2
- 239000011247 coating layer Substances 0.000 abstract 2
- 229940075534 amino methacrylate copolymer Drugs 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000003995 emulsifying agent Substances 0.000 abstract 1
- 239000000314 lubricant Substances 0.000 abstract 1
- 230000007935 neutral effect Effects 0.000 abstract 1
- 239000004014 plasticizer Substances 0.000 abstract 1
- 229920006163 vinyl copolymer Polymers 0.000 abstract 1
- 229920002554 vinyl polymer Polymers 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Inorganic Chemistry (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La invención trata sobre una composición farmacéutica de liberación controlada, que consta de un núcleo, que consta de un ingrediente farmacéutico activo, donde el núcleo está revestido por una capa de revestimiento que proporciona resistencia y que tiene el efecto de proporcionar el perfil de liberación del ingrediente farmacéutico activo para que sea resistente a la influencia del etanol, en donde la capa de revestimiento que proporciona resistencia al etanol consta de al menos 70% por peso de una mezcla de una porción polimérica a) y una porción de excipientes b), donde la porción polimérica a) está presente en una cantidad de al menos 3.0% por peso calculada en el peso del núcleo y donde la porción polimérica a) consta de una mezcla de polímeros a1) y a2) con a1) 60 a 99% por peso, con base en el peso en seco de la mezcla polimérica, de un polímero de vinilo o un copolímero de vinilo esencialmente neutral insoluble en agua, y a2) 1 a 40% por peso, con base en el peso seco de la mezcla polimérica, de un copolímero amino (met) acrilato, que es soluble en un medio acuoso amortiguado hasta de ph 4.0 e insoluble al menos por encima de ph 5.0 y la porción de excipientes b) que consta de los excipientes b1) 60 a 250% por peso de un lubricante inerte no poroso b2) 0.1 a 25% por peso de un emulsionante y además o de manera alternativa a b2) b3) 0.1 a 30% por peso de un plastificante y de forma opcional b4) 1 - 35% por peso de un compuesto celulósico. donde los excipientes de la porción de excipientes b) se calculan en peso en seco de la porción polimérica a).
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2009/053177 WO2010105673A1 (en) | 2009-03-18 | 2009-03-18 | Controlled release pharmaceutical composition with resistance against the influence of ethanol employing a coating comprising a polymer mixture and excipients |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2011009669A true MX2011009669A (es) | 2011-12-14 |
Family
ID=40752823
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2011009669A MX2011009669A (es) | 2009-03-18 | 2009-03-18 | Composición farmacéutica de liberación controlada con resistencia a la influencia de etanol mediante un revestimiento compuesto de una mezcla polimérica y excipientes. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20110311631A1 (es) |
| EP (1) | EP2408437A1 (es) |
| JP (1) | JP5619131B2 (es) |
| KR (1) | KR20120003436A (es) |
| CN (1) | CN102365083A (es) |
| BR (1) | BRPI0924427A2 (es) |
| CA (1) | CA2755814A1 (es) |
| IL (1) | IL214612A0 (es) |
| MX (1) | MX2011009669A (es) |
| WO (1) | WO2010105673A1 (es) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX339408B (es) * | 2010-03-09 | 2016-05-24 | Alkermes Pharma Ireland Ltd | Composiciones farmaceuticas entericas resistentes al alcohol. |
| ES2408343B2 (es) | 2010-05-10 | 2014-07-17 | Euro-Celtique, Sa | Composiciones farmacéuticas que comprenden hidromorfona y naloxona |
| MX344846B (es) | 2010-05-10 | 2017-01-10 | Euro-Celtique S A * | Combinacion de granulos cargados activos con activos adicionales. |
| US9993433B2 (en) | 2010-05-10 | 2018-06-12 | Euro-Celtique S.A. | Manufacturing of active-free granules and tablets comprising the same |
| BR112013027484A8 (pt) | 2011-06-17 | 2022-07-05 | Evonik Roehm Gmbh | Composição farmacêutica ou nutracêutica com resistência gástrica, e uso de um polímero de (met)acrilato |
| US9844511B2 (en) * | 2011-06-17 | 2017-12-19 | Evonik Roehm Gmbh | Coating composition suitable for pharmaceutical or nutraceutical dosage forms |
| US9668977B2 (en) | 2011-06-17 | 2017-06-06 | Evonik Röhm Gmbh | Coating composition suitable for pharmaceutical or nutraceutical dosage forms |
| FR2986431B1 (fr) * | 2012-02-03 | 2017-03-17 | Servier Lab | Composition pharmaceutique a liberation prolongee de trimetazidine, son procede de fabrication et son utilisation dans des traitements therapeutiques |
| WO2014011830A1 (en) | 2012-07-12 | 2014-01-16 | Mallinckrodt Llc | Extended release, abuse deterrent pharmaceutical compositions |
| JP2015537029A (ja) | 2012-11-14 | 2015-12-24 | ダブリュー・アール・グレース・アンド・カンパニー−コーンW R Grace & Co−Conn | 生物学的に活性な物質及び不規則性無機酸化物を含有する組成物 |
| US20140141075A1 (en) | 2012-11-21 | 2014-05-22 | Warner Chilcott Company, Llc | 5-aminosalicylic acid capsule formulation |
| EP2945994B1 (en) | 2013-01-18 | 2018-07-11 | Basf Se | Acrylic dispersion-based coating compositions |
| JP6150564B2 (ja) * | 2013-03-08 | 2017-06-21 | 杏林製薬株式会社 | 口腔内速崩壊性錠剤 |
| US10064826B2 (en) * | 2013-03-15 | 2018-09-04 | Navinta, Llc | Direct compression and dry granulation processes for preparing carglumic acid tablets having less impurities than those produced by wet granulation process |
| JP6539274B2 (ja) | 2013-08-12 | 2019-07-03 | ファーマシューティカル マニュファクチュアリング リサーチ サービシズ,インコーポレーテッド | 押出成形された即放性乱用抑止性丸剤 |
| EP3068397A1 (en) | 2013-11-13 | 2016-09-21 | Euro-Celtique S.A. | Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome |
| US10172797B2 (en) | 2013-12-17 | 2019-01-08 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
| US9492444B2 (en) | 2013-12-17 | 2016-11-15 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
| WO2016010771A1 (en) | 2014-07-17 | 2016-01-21 | Pharmaceutical Manufacturing Research Services, Inc. | Immediate release abuse deterrent liquid fill dosage form |
| JP2017531026A (ja) | 2014-10-20 | 2017-10-19 | ファーマシューティカル マニュファクチュアリング リサーチ サービシズ,インコーポレーテッド | 徐放性乱用抑止性液体充填剤形 |
| EP3288556A4 (en) | 2015-04-29 | 2018-09-19 | Dexcel Pharma Technologies Ltd. | Orally disintegrating compositions |
| HK1256865A1 (zh) * | 2016-02-03 | 2019-10-04 | Novartis Ag | 有机化合物的盖伦制剂 |
| US10076494B2 (en) | 2016-06-16 | 2018-09-18 | Dexcel Pharma Technologies Ltd. | Stable orally disintegrating pharmaceutical compositions |
| CN106727435B (zh) * | 2016-12-26 | 2020-06-02 | 浙江工业大学 | 一种美托洛尔缓释胶囊及其制备方法 |
| WO2018183881A1 (en) * | 2017-03-31 | 2018-10-04 | Acura Pharmaceuticals, Inc. | Methods and compositions for self-regulated release of active pharmaceuticals ingredients |
| MX2020002790A (es) | 2017-09-14 | 2020-08-20 | Evonik Operations Gmbh | Polimero y forma de dosis con propiedades de liberacion sostenida y resistencia contra la influencia de etanol. |
| MX2020005438A (es) | 2017-12-20 | 2020-12-03 | Purdue Pharma Lp | Formas de dosificacion de sulfato de morfina disuasivas del abuso. |
| WO2019170485A1 (en) | 2018-03-09 | 2019-09-12 | Evonik Röhm Gmbh | Polymer mixture with resistance against the influence of ethanol |
| KR102138253B1 (ko) * | 2018-08-17 | 2020-07-29 | 한국유나이티드제약 주식회사 | 실로스타졸 서방성 제제 |
| EP3883549A1 (en) * | 2018-11-19 | 2021-09-29 | Jazz Pharmaceuticals Ireland Limited | Alcohol-resistant drug formulations |
| TW202139986A (zh) | 2020-02-21 | 2021-11-01 | 愛爾蘭商爵士製藥愛爾蘭有限責任公司 | 治療原發性嗜睡症之方法 |
| CN112294777B (zh) * | 2020-11-04 | 2022-07-05 | 南京康川济医药科技有限公司 | 一种盐酸伊伐布雷定缓释制剂及其制备方法和应用 |
| EP4366710A1 (en) * | 2021-07-09 | 2024-05-15 | Evonik Operations GmbH | Composition comprising a (meth)acrylate copolymer, an alkali or ammonium salt of a saturated aliphatic monocarboxylic acid and specific glidants |
| CN113925838B (zh) * | 2021-11-11 | 2022-11-11 | 乐普制药科技有限公司 | 一种依帕司他与西格列汀或其可药用盐的复方缓释片及其制备方法 |
| EP4527411A1 (en) * | 2022-05-18 | 2025-03-26 | Towa Pharmaceutical Co., Ltd. | Membrane-forming composition, membrane-like composition, and use of same |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2655266B1 (fr) * | 1989-12-05 | 1992-04-03 | Smith Kline French Lab | Compositions pharmaceutiques a base de cimetidine. |
| US5102668A (en) * | 1990-10-05 | 1992-04-07 | Kingaform Technology, Inc. | Sustained release pharmaceutical preparation using diffusion barriers whose permeabilities change in response to changing pH |
| AU5775398A (en) * | 1996-12-17 | 1998-07-15 | Poli Industria Chimica S.P.A. | Site-specific controlled release dosage formulation for mesalamine |
| US6524620B2 (en) * | 1998-07-20 | 2003-02-25 | Andrx Pharmaceuticals, Inc. | Diltiazem controlled release formulation and method of manufacture |
| DE19918435A1 (de) * | 1998-07-23 | 2000-01-27 | Roehm Gmbh | Überzugs- und Bindemittel für orale oder dermale Arzneiformen |
| US20030118641A1 (en) * | 2000-07-27 | 2003-06-26 | Roxane Laboratories, Inc. | Abuse-resistant sustained-release opioid formulation |
| US20030044458A1 (en) * | 2001-08-06 | 2003-03-06 | Curtis Wright | Oral dosage form comprising a therapeutic agent and an adverse-effect agent |
| DE10208335A1 (de) * | 2002-02-27 | 2003-09-04 | Roehm Gmbh | Arzneiform und Verfahren zu ihrer Herstellung |
| AU2003270349A1 (en) * | 2002-09-09 | 2004-03-29 | Biovail Laboratories International S.R.L. | Chronotherapeutic diltiazem formulations and the administration thereof |
| DE10250543A1 (de) * | 2002-10-29 | 2004-05-19 | Röhm GmbH & Co. KG | Mehrschichtige Arzneiform |
| US20040202717A1 (en) * | 2003-04-08 | 2004-10-14 | Mehta Atul M. | Abuse-resistant oral dosage forms and method of use thereof |
| AU2004285284B2 (en) * | 2003-10-31 | 2010-03-25 | Hexal Ag | A process for the preparation of an active-ingredient-containing formulation with a coating |
| BRPI0606339A2 (pt) * | 2005-01-28 | 2009-06-16 | Euro Celtique Sa | formas farmacêuticas resistentes a álcool |
| DE102005024614A1 (de) * | 2005-05-25 | 2006-11-30 | Röhm Gmbh | Verwendung von Polymermischungen zur Herstellung von überzogenen Arzneiformen sowie Arzneiform mit polymerem Mischüberzug |
| WO2007085024A2 (en) * | 2006-01-21 | 2007-07-26 | Abbott Gmbh & Co. Kg | Dosage form and method for the delivery of drugs of abuse |
| DE102006051020A1 (de) * | 2006-10-26 | 2008-04-30 | Evonik Röhm Gmbh | Verwendung von (Meth)acrylat-Copolymeren in Retard-Arzneiformen zur Verringerung des Einflusses von Ethanol auf die Wirkstofffreisetzung |
| JP5965583B2 (ja) * | 2007-08-13 | 2016-08-10 | インスピリオン デリバリー テクノロジーズ エルエルシー | 乱用抵抗性医薬組成物、その使用方法および作製方法 |
| US9700520B2 (en) * | 2007-09-21 | 2017-07-11 | Evonik Roehm Gmbh | PH-dependent controlled release pharmaceutical opioid composition with resistance against the influence of ethanol |
-
2009
- 2009-03-18 MX MX2011009669A patent/MX2011009669A/es active IP Right Grant
- 2009-03-18 BR BRPI0924427A patent/BRPI0924427A2/pt not_active IP Right Cessation
- 2009-03-18 EP EP09779170A patent/EP2408437A1/en not_active Withdrawn
- 2009-03-18 JP JP2012500079A patent/JP5619131B2/ja not_active Expired - Fee Related
- 2009-03-18 KR KR1020117021575A patent/KR20120003436A/ko not_active Ceased
- 2009-03-18 CA CA2755814A patent/CA2755814A1/en not_active Abandoned
- 2009-03-18 US US13/203,760 patent/US20110311631A1/en not_active Abandoned
- 2009-03-18 WO PCT/EP2009/053177 patent/WO2010105673A1/en not_active Ceased
- 2009-03-18 CN CN2009801581095A patent/CN102365083A/zh active Pending
-
2011
- 2011-08-11 IL IL214612A patent/IL214612A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP5619131B2 (ja) | 2014-11-05 |
| EP2408437A1 (en) | 2012-01-25 |
| BRPI0924427A2 (pt) | 2016-01-26 |
| CN102365083A (zh) | 2012-02-29 |
| WO2010105673A1 (en) | 2010-09-23 |
| CA2755814A1 (en) | 2010-09-23 |
| US20110311631A1 (en) | 2011-12-22 |
| JP2012520832A (ja) | 2012-09-10 |
| KR20120003436A (ko) | 2012-01-10 |
| IL214612A0 (en) | 2011-09-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2011009669A (es) | Composición farmacéutica de liberación controlada con resistencia a la influencia de etanol mediante un revestimiento compuesto de una mezcla polimérica y excipientes. | |
| MX2011009667A (es) | Composición farmacéutica de liberación controlada con resistencia a la influencia de etanol mediante el uso de un revestimiento compuesto de polímeros de vinilo neutrales y excipientes. | |
| MX347227B (es) | Composicion farmaceutica o nutraceutica con liberacion sostenida caracteristica y con resistencia contra la influencia del etanol. | |
| WO2010064126A3 (en) | Controlled release dosage forms | |
| MX355662B (es) | Composicion farmaceutica o nutraceutica de resistencia gastrica con resistencia contra la influencia de etanol. | |
| WO2012085043A3 (en) | Rapidly disintegrating, solid coated dosage form | |
| BRPI0720626A2 (pt) | Composição formadora de película, nanopartículas modificadas, revestimento resistente a risco, usos de um copolímero segmentado, e de nanopartículas modificadas | |
| MX358196B (es) | Composicion farmaceutica o nutraceutica con caracteristica de liberacion sostenida y con resistencia contra la influencia del etanol. | |
| MX2017006858A (es) | Composición farmacéutica o nutracéutica con resistencia a la influencia del etanol. | |
| WO2010005726A3 (en) | Therapeutic polymeric nanoparticles with mtor inhibitors and methods of making and using same | |
| NZ600123A (en) | Compressible-coated pharmaceutical compositions and tablets and methods of manufacture | |
| MX376383B (es) | Composicion farmaceutica o nutraceutica con resistencia contra la influencia del etanol | |
| BRPI0823128A2 (pt) | Composição farmacêutica de liberação controlada dependente do ph para não opioides com resistência contra a influência de etanol. | |
| WO2009123759A3 (en) | Therapeutic uses of biocompatible biogel compositions | |
| BR112014002837A2 (pt) | dispersão aquosa com baixo teor de formaldeído de um copolímero de vinil éster/etileno preparado por meio de copolimerização de emulsão de uma mistura de monômero; composição de adesivo; produto de cigarro; e uso da composição de adesivo | |
| WO2010106314A3 (en) | Formulation comprising avermectin particles coated with a photo - protecting agent | |
| WO2009121970A3 (de) | Schichtmaterial | |
| MX356579B (es) | Composicion farmaceutica o nutraceutica de resistencia gastrica con resistencia contra la influenza de etanol. | |
| WO2010005732A3 (en) | Composition and method of preparation of release systems for constant (zero-order) release of active agents | |
| WO2014106116A3 (en) | Therapeutic compositions comprising antibodies | |
| WO2013012666A3 (en) | Compounds, methods of making, and methods of use | |
| WO2014179615A3 (en) | Biodegradable copolymers, forming and using same | |
| BR112012022363A2 (pt) | forma de dosagem com liberação modificada | |
| BR112013020581A2 (pt) | "composição agroquímica, método de preparação da composição, uso de um copolímero e método de controle de fungos fitopatogênicos" | |
| WO2012092486A3 (en) | Modified release benzimidazole formulations |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |